Acumen earnings released on October 26, 2026, showed a narrower third-quarter net loss and $78.6 million in cash, cash equivalents and marketable securities. The Alzheimer’s drug developer expects those resources to support current activities into early 2027, with Phase 2 results for its lead candidate, sabirnetug, due in November 2026.
Key Takeaways
- Third-quarter net loss narrowed to $25.4 million from $26.5 million a year earlier.
- Management expects existing cash resources to support current clinical and operational activities into early 2027.
- November’s planned ALTITUDE-AD readout will cover clinical efficacy, safety and key biomarkers.
Acumen earnings reflect lower trial-related spending
Acumen’s third-quarter financial results show research and development expenses of $21.1 million for the quarter ended September 30, 2026, compared with $22.0 million a year earlier. The company attributed the decline primarily to lower manufacturing, materials and contract research organization costs associated with ALTITUDE-AD, partly offset by higher spending on its Enhanced Brain Delivery program.
General and administrative expenses increased to $4.7 million from $4.5 million. Operating loss narrowed to $25.8 million from $26.5 million, while net loss per share was $0.35, compared with $0.44 in the prior-year quarter.
| Item | Details |
|---|---|
| Trial enrollment | 542 participants with early Alzheimer’s disease |
| Treatment groups | 35 mg/kg sabirnetug, 50 mg/kg sabirnetug, or placebo |
| Dosing schedule | Intravenous infusions once every four weeks |
| Controlled study period | 18 months, double-blind |
Cash runway extends beyond the planned readout
Cash, cash equivalents and marketable securities declined from $110.2 million at June 30 to $78.6 million at September 30, 2026. The early-2027 runway is management’s forecast for funding current clinical and operational activities, not a guarantee of funding through later development stages.
The forecast places the expected November trial results within the stated funding window. Separately, Acumen is targeting a mid-2027 investigational new drug application for a lead candidate in its Enhanced Brain Delivery program; that milestone falls beyond the currently stated cash runway.
What the November ALTITUDE-AD results will test
ALTITUDE-AD is evaluating whether sabirnetug can slow cognitive and functional decline in people with early Alzheimer’s disease. The investigational antibody selectively targets soluble amyloid beta oligomers, rather than amyloid plaques.
The planned topline release includes the primary efficacy measure, the Integrated Alzheimer’s Disease Rating Scale, or iADRS. It is also expected to include secondary outcomes such as Clinical Dementia Rating–Sum of the Boxes, adverse-event rates including amyloid-related imaging abnormalities, and key biomarkers.
These are planned disclosures, not clinical findings. The trial’s efficacy and safety results had not been announced in the October 26 update.
Next milestone
The next scheduled milestone is the November 2026 ALTITUDE-AD topline readout, which is expected to provide the primary efficacy results alongside safety and biomarker data.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
Comments
Be respectful. No spam, impersonation or private credentials. Ordinary posts and comments appear immediately; suspicious links are held for review.
Please wait…